About Rachael Hagan
Form D filings for NephroDI Therapeutics from 2021 to 2024 list Rachael Hagan as president and director.
Rachael Hagan first appears on SEC filings in 2021.
Experience
This experience comes from SEC filings. The years are when the filings name Rachael Hagan in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Rachael Hagan works with at each company, as listed on that company's latest Form D.
NephroDI Therapeutics, Inc. · Form D, Jun 18, 2024